Skip to content
value.today
Amyris Biotechnologies Inc. logo

Amyris Biotechnologies Inc.

Total raised
$1.3 B
35 rounds on record
Latest round
$8 M
Sep 2022
First round on record
Feb 2008
Today
Private
See the company page

Amyris Biotechnologies Inc. is listed today as Amyris Inc.: market value, financials and filings are on its company page.

Funding rounds

35 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Amyris Biotechnologies Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2022$8 MNo. 35$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 35, Sep 2022

Investors in this round

1 investor had bought by the notice of Sep 28, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • Hermanus Kieftenbeld · Executive Officer · Chief Financial Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Nicole Kelsey · Executive Officer · Chief Legal Officer & Secretary
  • Ana John Dutra · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James John Mccann · Director
  • Julie John Washington · Director
  • L John Doerr · Director
  • Lisa John Qi · Director
  • Philip John Eykerman · Director
  • Ryan John Panchadsaram · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by Issuer upon exercise of warrant issued to purchase up to 2,046,036 shares of common stock @ $3.91/share as described in the Current Report on Form 8-K filed September 13, 2022.”

Signed by Nicole Kelsey, Chief legal officer and secretary. Source: SEC Form D, newest notice filed Sep 28, 2022. Read the notice at the SEC.

equity, optionsSEC
Jun 2020$200 MNo. 34$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 34, Jun 2020

Investors in this round

53 investors had bought by the notice of Jun 22, 2020: 53 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$200 M of $200 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$9,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • Han John Keiftenbeld · Executive Officer · Chief Financial Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James John Mccann · Director
  • L John Doerr · Director
  • Lisa John Qi · Director
  • Patrick John Yang · Director
  • Philip John Eykerman · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JEFFERIES LLC (CRD 2347) · New York, New YorkSold in all US states
  • COWEN AND COMPANY, LLC (CRD 7616) · New York, New YorkSold in all US states
  • OPPENHEIMER & CO. INC. (CRD 249) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “Issuer sold 32,614,573 shares of common stock and 102,156.21 shares of Series E Convertible Preferred Stock, convertible into 34,052,070 shares of common stock, as described in Current Reports on Form 8-K filed with the SEC on June 4 and June 10, 2020.”

Signed by Nicole Kelsey, General counsel and secretary. Source: SEC Form D, newest notice filed Jun 22, 2020. Read the notice at the SEC.

equitySEC
Jan 2020$94 MNo. 33$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 33, Jan 2020

Investors in this round

7 investors had bought by the notice of Feb 18, 2020: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$94 M of $94 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold 13,989,973 shares of common stock and rights to purchase 18,649,961 shares of common stock, as described in a Current Report on Form 8-K filed February 6, 2020. Includes amount that may be received upon exercise of rights.”

Signed by Nicole Kelsey, General counsel and secretary. Source: SEC Form D, newest notice filed Feb 18, 2020. Read the notice at the SEC.

equity, optionsSEC
Jan 2020$10 MNo. 32$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 32, Jan 2020

Investors in this round

4 investors had bought by the notice of Jan 29, 2020: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by Issuer upon exercise of warrants issued to purchase up to 3,000,000 shares of common stock @ $3.25/share and other non-cash consideration as further described in the Current Report on Form 8-K filed January 21,2020.”

Signed by Nicole Kelsey, General counsel and secretary. Source: SEC Form D, newest notice filed Jan 29, 2020. Read the notice at the SEC.

equity, optionsSEC
Nov 2019$4 MNo. 31$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 31, Nov 2019

Investors in this round

1 investor had bought by the notice of Dec 12, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by Issuer upon exercise of warrant issued to purchase up to 1,000,000 shares of common stock @ $3.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed December 2, 2019.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Dec 12, 2019. Read the notice at the SEC.

equity, optionsSEC
Nov 2019$8 MNo. 30$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 30, Nov 2019

Investors in this round

2 investors had bought by the notice of Nov 29, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by Issuer upon exercise of warrants issued to purchase 2,028,423 shares of common stock @ $3.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed November 20, 2019.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Nov 29, 2019. Read the notice at the SEC.

equity, optionsSEC
Oct 2019$8 MNo. 29$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 29, Oct 2019

Investors in this round

1 investor had bought by the notice of Nov 12, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by issuer upon exercise of warrant issued to purchase up to 2,000,000 shares of common stock @ $3.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed November 1, 2019.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Nov 12, 2019. Read the notice at the SEC.

equity, optionsSEC
Oct 2019$6 MNo. 28$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 28, Oct 2019

Investors in this round

1 investor had bought by the notice of Oct 25, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by issuer upon exercise of warrant issued to purchase up to 2,000,000 shares of common stock @ $2.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed October 16, 2019.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Oct 25, 2019. Read the notice at the SEC.

equity, optionsSEC
Sep 2019$13 MNo. 27$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 27, Sep 2019

Investors in this round

3 investors had bought by the notice of Sep 25, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by issuer upon exercise of warrants issued to purchase 3,205,128 shares of common stock @ $3.90/share and other non-cash consideration as further described in the Current Report on Form 8-K filed September 11, 2019.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Sep 25, 2019. Read the notice at the SEC.

equity, optionsSEC
Aug 2019$19 MNo. 26$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 26, Aug 2019

Investors in this round

1 investor had bought by the notice of Sep 12, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$19 M of $19 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by issuer upon exercise of warrant issued to purchase 4,871,795 shares of common stock @ $3.90/share and other non-cash consideration as further described in the Current Report on Form 8-K filed September 4, 2019.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Sep 12, 2019. Read the notice at the SEC.

equity, optionsSEC
Aug 2019$10 MNo. 25$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 25, Aug 2019

Investors in this round

2 investors had bought by the notice of Aug 29, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer
  • Kathleen Valiasek · Executive Officer · Chief Business Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • James Neil Mccann · Director
  • L John Doerr · Director
  • Lisa Neil Qi · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by issuer upon exercise of warrants issued to purchase 3,438,829 shares of common stock @ $2.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed August 20, 2019.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Aug 29, 2019. Read the notice at the SEC.

equity, optionsSEC
Apr 2019$75 MNo. 24$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 24, Apr 2019

Investors in this round

9 investors had bought by the notice of May 9, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$725,300
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • Joel Cherry · Executive Officer · President of R&D
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Kathleen Valiasek · Executive Officer · Chief Financial Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Christophe John Vuillez · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Oppenheimer & Co. Inc. (CRD 249) · New York, New YorkSold in CA

Remarks in the notice

  • On the amounts: “Issuer sold 7,356,913 shares of common stock and warrants to purchase 8,084,770 shares of common stock, as described in a Current Report on Form 8-K filed April 30, 2019. Includes amount that may be received upon exercise of warrants.”
  • On the use of proceeds: “Proceeds from the offering may be used to pay amounts owing under a loan and security agreement with Foris Ventures, LLC, which is owned by director John Doerr.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed May 9, 2019. Read the notice at the SEC.

equity, optionsSEC
Apr 2019$36 MNo. 23$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 23, Apr 2019

Investors in this round

1 investor had bought by the notice of Apr 30, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$36 M of $36 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • Joel Cherry · Executive Officer · President of R&D
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Kathleen Valiasek · Executive Officer · Chief Financial Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Christophe John Vuillez · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold 6,732,369 shares of common stock and warrants to purchase 5,424,804 shares of common stock at $2.87/share, as described in a Current Report on Form 8-K filed April 19, 2019. Includes amount that may be received upon exercise of warrants.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Apr 30, 2019. Read the notice at the SEC.

equity, optionsSEC
Dec 2018$60 MNo. 22$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 22, Dec 2018

Investors in this round

2 investors had bought by the notice of Dec 21, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kathleen Valiasek · Executive Officer
  • Nicole Kelsey · Executive Officer
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Christophe John Vuillez · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Oppenheimer & Co. Inc. (CRD 249) · New York, New YorkSold in CA

Remarks in the notice

  • On fees: “Represents placement agent fee. Issuer also paid an advisory fee of $600,000 in connection with the transaction.”
  • On the amounts: “Issuer sold and issued senior convertible notes in the aggregate amount of $60M to investors under a Securities Purchase Agreement as further described in Current Reports on Form 8-K filed December 7, 2018 and December 11, 2018.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Dec 21, 2018. Read the notice at the SEC.

equity, debt, optionsSEC
Nov 2018$7 MNo. 21$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 21, Nov 2018

Investors in this round

1 investor had bought by the notice of Dec 4, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kathleen Valiasek · Executive Officer
  • Nicole Kelsey · Executive Officer
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Christophe John Vuillez · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents the value of certain non-cash consideration received by the issuer as further described in the Current Report on Form 8-K filed November 26, 2018.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Dec 4, 2018. Read the notice at the SEC.

equitySEC
Aug 2018$91 MNo. 20$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 20, Aug 2018

Investors in this round

3 investors had bought by the notice of Aug 31, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$91 M of $91 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer · Chief Operating Officer
  • Joel Cherry · Executive Officer · President of R&D
  • John Melo · Executive Officer, Director · President and Chief Executive Officer
  • Kathleen Valiasek · Executive Officer · Chief Financial Officer
  • Nicole Kelsey · Executive Officer · General Counsel & Secretary
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Christophe John Vuillez · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director
  • Steven John Mills · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amount that may be received by issuer upon exercise of warrants issued to purchase 12,097,164 shares of common stock @ $7.52/share and other non-cash consideration as further described in the Current Report on Form 8-K filed August 20, 2018.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Aug 31, 2018. Read the notice at the SEC.

equity, optionsSEC
Apr 2018$38 MNo. 19$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 19, Apr 2018

Investors in this round

11 investors had bought by the notice of Apr 27, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M of $38 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eduardo Alvarez · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kathleen Valiasek · Executive Officer
  • Nicole Kelsey · Executive Officer
  • Carole John Piwnica · Director
  • Christoph John Goppelsroeder · Director
  • Christophe John Vuillez · Director
  • Fernando John Reinach · Director
  • Frank John Kung · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Issuer paid an advisory fee of $450,000 in connection with this transaction.”
  • On the amounts: “Includes amount that may be received by issuer upon exercise of warrants issued to purchase 3,616,174 shares of common stock @ $7.00/share and other non-cash consideration as further described in the Current Report on Form 8-K filed April 12, 2018.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Apr 27, 2018. Read the notice at the SEC.

equity, optionsSEC
Aug 2017$25 MNo. 18$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 18, Aug 2017

Investors in this round

1 investor had bought by the notice of Aug 17, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kathleen Valiasek · Executive Officer
  • Nicole Kelsey · Executive Officer · Nicole Kelsey began serving as General Counsel on August 7, 2017.
  • Bram John Klaeijsen · Director
  • Carole John Piwnica · Director
  • Christophe John Vuillez · Director
  • Fernando John Reinach · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R Neil Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold and issued 25,000 shares of Series B preferred stock and issued warrants to purchase 3,968,116 shares of common stock to an investor under a Securities Purchase Agreement, as further described on Form 8-K filed on August 3, 2017.”

Signed by Nicole Kelsey, General counsel. Source: SEC Form D and 1 amendment, newest notice filed Aug 17, 2017. Read the notice at the SEC.

equity, optionsSEC
May 2017$6 MNo. 17$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 17, May 2017

Investors in this round

1 investor had bought by the notice of Jun 14, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kathleen Valiasek · Executive Officer
  • Bram John Klaeijsen · Director
  • Carole John Piwnica · Director
  • Christophe John Vuillez · Director
  • Fernando John Reinach · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L. John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director
  • R. Neil Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold and issued 5,700 shares of Series B preferred stock and issued warrants to purchase 13,570,958 shares of common stock to an investor under a Securities Purchase Agreement, as further described on Form 8-K filed on June 6, 2017.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Jun 14, 2017. Read the notice at the SEC.

equity, optionsSEC
May 2017$65 MNo. 16$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 16, May 2017

Investors in this round

22 investors had bought by the notice of May 23, 2017: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$499,928
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kathleen Valiasek · Executive Officer
  • Bram John Klaeijsen · Director
  • Carole John Piwnica · Director
  • Christophe John Vuillez · Director
  • Fernando John Reinach · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L. John Doerr · Director
  • Patrick Neil Yang · Director
  • Philip John Eykerman · Director · Mr. Eykerman was appointed to the Board of Directors on May 18, 2017.
  • R. Neil Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Placement agent fee.”
  • On the amounts: “Issuer sold and issued 65,203.8756 shares of Series B preferred stock and issued warrants to purchase 207,954,414 shares of common stock to investors under a Securities Purchase Agreement, as further described on Form 8-K filed on May 8, 2017.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed May 23, 2017. Read the notice at the SEC.

equity, optionsSEC
Nov 2016$6 MNo. 15$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 15, Nov 2016

Investors in this round

1 investor had bought by the notice of Nov 30, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Raffi Asadorian · Executive Officer
  • Abraham John Klaeijsen · Director
  • Carole John Piwnica · Director
  • Christophe Vuillez · Director
  • Fernando John Reinach · Director
  • Geoffrey John Duyk · Director
  • Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Margo John Georgiadis · Director
  • Patrick Neil Yang · Director
  • R Neil Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering includes amount that may be received by issuer upon exercise of warrant issued to purchase 10,000,000 shares of common stock @ $.50/share, as further described in Current Reports on Form 8-K filed November 1, 2016 and November 18, 2016.”

Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Nov 30, 2016. Read the notice at the SEC.

equity, optionsSEC
Aug 2016$3 MNo. 14$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 14, Aug 2016

Investors in this round

1 investor had bought by the notice of Aug 19, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Raffi Asadorian · Executive Officer
  • Abraham John Klaeijsen · Director
  • Carole John Piwnica · Director
  • Fernando John Reinach · Director
  • Geoffrey John Duyk · Director
  • Hh Sheik Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Margo John Georgiadis · Director
  • Patrick Neil Yang · Director
  • Philippe Boisseau · Director
  • R Neil Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering includes amount that may be received by issuer upon exercise of warrant issued to purchase 5,000,000 shares of common stock @ $.50/share and other non-cash consideration, as further described in Quarterly Report on Form 10-Q filed August 9, 2016.”

Signed by Chris Jaenike, Assistant secretary. Source: SEC Form D, newest notice filed Aug 19, 2016. Read the notice at the SEC.

equity, optionsSEC
May 2016$5 MNo. 13$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 13, May 2016

Investors in this round

1 investor had bought by the notice of May 24, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Nicholas Khadder · Executive Officer
  • Raffi Asadorian · Executive Officer
  • Abraham John Klaeijsen · Director
  • Carole John Piwnica · Director
  • Fernando John Reinach · Director
  • Geoffrey John Duyk · Director
  • Hh Shiek Abdullah Bin Khalifa Neil Al Thani · Director
  • L John Doerr · Director
  • Margo John Georgiadis · Director
  • Patrick Neil Yang · Director
  • Philippe Boisseau · Director
  • R Neil Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold and issued 4,385,964 shares of common stock at $1.14 per share under a Securities Purchase Agreement, as further described in a Current Report on Form 8-K filed on May 13, 2016.”

Signed by Nicholas Khadder, Secretary. Source: SEC Form D, newest notice filed May 24, 2016. Read the notice at the SEC.

equitySEC
Feb 2016$20 MNo. 12$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 12, Feb 2016

Investors in this round

3 investors had bought by the notice of Feb 25, 2016: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Nicholas Khadder · Executive Officer
  • Raffi Asadorian · Executive Officer
  • Abraham Klaeijsen · Director
  • Carole Piwnica · Director
  • Fernando Reinach · Director
  • Geoffrey Duyk · Director
  • HH Sheikh Abdullah bin Khalifa Al Thani · Director
  • John Doerr · Director
  • Margaret Georgiadis · Director
  • Patrick Neil Yang · Director
  • Philippe Boisseau · Director
  • R Neil Williams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold and issued unsecured promissory notes in the amount of $20M and warrants to purchase 2,857,142 shares of common stock to investors under a Note and Warrant Purchase Agreement, as further described on Form 8-K filed on February 19, 2016.”

Signed by Nicholas Khadder, Secretary. Source: SEC Form D, newest notice filed Feb 25, 2016. Read the notice at the SEC.

debt, optionsSEC
Jul 2015$141 MNo. 11$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 11, Jul 2015

Investors in this round

2 investors had bought by the notice of Aug 12, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$141 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Nicholas Khadder · Executive Officer
  • Raffi Asadorian · Executive Officer
  • Abraham John Klaeijsen · Director
  • Fernando John Reinach · Director
  • Geoffrey John Duyk · Director
  • L John Doerr · Director
  • Patrick Neil Yang · Director
  • Philippe Boisseau · Director
  • Piwnica John Carole · Director
  • R Neil Williams · Director
  • Sheikh Abdullah Bin Khalifa Neil Al Thani · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer sold and issued approx. $141 million in common stock as part of exchange of convertible notes. Exchange price was $2.30 per share and Issuer also issued various warrants to Total and Temasek, as further described on Form 8-K filed on July 30, 2015.”

Signed by Nicholas Khadder, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Aug 12, 2015. Read the notice at the SEC.

equitySEC
Apr 2014$4 MNo. 10$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 10, Apr 2014

Investors in this round

1 investor had bought by the notice of Apr 23, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Nicholas Khadder · Executive Officer
  • Paulo Diniz · Executive Officer
  • Susanna Mcferson · Executive Officer
  • Arthur Levinson · Director
  • Carole Piwnica · Director
  • Fernando Reinach · Director
  • Geoffrey Duyk · Director
  • John Doerr · Director
  • Nam-Hai Chua · Director
  • Neil Williams · Director
  • Philippe Boisseau · Director
  • Sheikh Abdullah Bin Khalifa Al Thani · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nicholas Khadder, General Counsel. Source: SEC Form D, newest notice filed Apr 23, 2014. Read the notice at the SEC.

equitySEC
Mar 2013$5 MNo. 9$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 9, Mar 2013

Investors in this round

1 investor had bought by the notice of Apr 16, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary Loeb · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Paulo Diniz · Executive Officer
  • Steven R. Mills · Executive Officer
  • Susanna Mcferson · Executive Officer
  • Arthur R. Levinson · Director
  • Carole R. Piwnica · Director
  • Fernando R. Reinach · Director
  • Geoffrey R. Duyk · Director
  • John R. Doerr · Director
  • Nam-Hai R. Chua · Director
  • Patrick R. Pichette · Director
  • Philippe R. Boisseau · Director
  • Ralph R. Alexander · Director
  • Sheikh Abdullah Bin Khalifa R. Al Thani · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary Loeb, SVP, General Counsel & Secretary. Source: SEC Form D, newest notice filed Apr 16, 2013. Read the notice at the SEC.

equitySEC
Dec 2012$42 MNo. 8$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 8, Dec 2012

Investors in this round

7 investors had bought by the notice of Jan 7, 2013: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$42 M of $42 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary Loeb · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Paulo Diniz · Executive Officer
  • Peter Boynton · Executive Officer
  • Steven R. Mills · Executive Officer
  • Arthur R. Levinson · Director
  • Carole R. Piwnica · Director
  • Fernando R. Reinach · Director
  • Geoffrey R. Duyk · Director
  • John R. Doerr · Director
  • Nam-Hai R. Chua · Director
  • Neil R. Renninger · Director
  • Patrick R. Pichette · Director
  • Philippe R. Boisseau · Director
  • Ralph R. Alexander · Director
  • Sheikh Abdullah Bin Khalifa R. Al Thani · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary Loeb, SVP, General Counsel & Secretary. Source: SEC Form D, newest notice filed Jan 7, 2013. Read the notice at the SEC.

equitySEC
May 2012$4 MNo. 7$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 7, May 2012

Investors in this round

5 investors had bought by the notice of Jun 5, 2012: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Mark R. Patel · Executive Officer
  • Paulo Diniz · Executive Officer
  • Steven R. Mills · Executive Officer
  • Arthur Levinson · Director
  • Carole Piwnica · Director
  • Fernando Reinach · Director
  • Geoffrey R. Duyk · Director
  • John Doerr · Director
  • Neil Renninger · Director
  • Patrick Pichette · Director
  • Phillippe Boisseau · Director
  • Ralph Alexander · Director
  • Sheikh Abdullah bin Khalifa R. Al Thani · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gary Loeb, SVP, General Counsel & Secretary. Source: SEC Form D, newest notice filed Jun 5, 2012. Read the notice at the SEC.

equitySEC
Feb 2012$59 MNo. 6$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 6, Feb 2012

Investors in this round

6 investors had bought by the notice of Mar 12, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$59 M of $59 M offered
Smallest investment taken
$499,998
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeryl Hilleman · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Mario Portela · Executive Officer
  • Neil Renninger · Executive Officer, Director
  • Paulo Diniz · Executive Officer
  • Tamara Tompkins · Executive Officer
  • Arthur Levinson · Director
  • Carole Piwnica · Director
  • Fernando Reinach · Director
  • John Doerr · Director
  • Patrick Pichette · Director
  • Phillippe Boisseau · Director
  • Ralph Alexander · Director
  • Samir Kaul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tamara Tompkins, EVP, General Counsel & Secretary. Source: SEC Form D, newest notice filed Mar 12, 2012. Read the notice at the SEC.

equitySEC
Oct 2011$7 MIssued in a merger or acquisition$2 to $10 million

Amyris Biotechnologies Inc.: Private sale, Oct 2011

Investors in this round

1 investor had bought by the notice of Oct 28, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeryl Hilleman · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Mario Portela · Executive Officer
  • Neil Renninger · Executive Officer, Director
  • Paulo Diniz · Executive Officer
  • Tamara Tompkins · Executive Officer
  • Arthur Levinson · Director
  • Carole Piwnica · Director
  • Fernando de Castro Reinach · Director
  • John Doerr · Director
  • Patrick Pichette · Director
  • Philippe Boisseau · Director
  • Ralph Alexander · Director
  • Samir Kaul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amyris, Inc. common stock in the amount of $7,000,000 (based on closing share prices of Amyris, Inc.'s publicly traded securities) was issued as partial consideration for purchase of substantially all of the Draths Corporation's assets.”
  • On the use of proceeds: “The offering was made as partial consideration for the purchase of substantially all of the assets of Draths Corporation by Amyris, Inc.”
  • On a merger: “The offering was made as partial consideration for the purchase of substantially all of the assets of Draths Corporation by Amyris, Inc.”

Signed by Tamara Tompkins, Executive Vice President, General Counsel, and Secretary. Source: SEC Form D, newest notice filed Oct 28, 2011. Read the notice at the SEC.

equitySEC
Sep 2010$14 MNo. 5$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 5, Sep 2010

Investors in this round

3 investors had bought by the notice of Oct 12, 2010: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jack Newman · Executive Officer
  • Jeff Lievense · Executive Officer
  • Jeryl Hilleman · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kinkead Reiling · Executive Officer, Director
  • Mario Portela · Executive Officer
  • Neil Renninger · Executive Officer
  • Peter Boynton · Executive Officer
  • Tamara Tompkins · Executive Officer
  • Arthur Levinson · Director
  • Carole Piwnica · Director
  • Fernando Reinach · Director
  • Geoff Duyk · Director
  • John Doerr · Director
  • Patrick Pichette · Director
  • Ralph Alexander · Director
  • Samir Kaul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tamara Tompkins, Secretary. Source: SEC Form D, newest notice filed Oct 12, 2010. Read the notice at the SEC.

equitySEC
Jun 2010$133 MNo. 4$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 4, Jun 2010

Investors in this round

1 investor had bought by the notice of Jul 2, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$133 M of $133 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jack Newman · Executive Officer
  • Jeff Lievense · Executive Officer
  • Jeryl Hilleman · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kinkead Reiling · Executive Officer, Director
  • Mario Portela · Executive Officer
  • Neil Renninger · Executive Officer
  • Peter Boynton · Executive Officer
  • Tamara Tompkins · Executive Officer
  • Arthur Levinson · Director
  • Carole Piwnica · Director
  • Fernando Reinach · Director
  • Geoff Duyk · Director
  • John Doerr · Director
  • Patrick Pichette · Director
  • Ralph Alexander · Director
  • Samir Kaul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tamara Tompkins, Secretary. Source: SEC Form D, newest notice filed Jul 2, 2010. Read the notice at the SEC.

equitySEC
Mar 2010$48 MNo. 3$10 to $50 million

Amyris Biotechnologies Inc.: Raise no. 3, Mar 2010

Investors in this round

1 investor had bought by the notice of Apr 2, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$48 M of $48 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Jack Newman · Executive Officer
  • Jeff Lievense · Executive Officer
  • Jeryl Hilleman · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kinkead Reiling · Executive Officer, Director
  • Neil Renninger · Executive Officer
  • Tamara Tompkins · Executive Officer
  • Carole Piwnica · Director
  • Fernando Reinach · Director
  • Geoff Duyk · Director
  • John Doerr · Director
  • Ralph Alexander · Director
  • Samir Kaul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tamara Tompkins, Secretary. Source: SEC Form D, newest notice filed Apr 2, 2010. Read the notice at the SEC.

equitySEC
Jul 2009$61 MNo. 2$50 to $250 million

Amyris Biotechnologies Inc.: Raise no. 2, Jul 2009

Investors in this round

34 investors had bought by the notice of Apr 2, 2010: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$61 M of $61 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Jack Newman · Executive Officer
  • Jeff Lievense · Executive Officer
  • Jeryl Hilleman · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kinkead Reiling · Executive Officer, Director
  • Neil Renninger · Executive Officer
  • Tamara Tompkins · Executive Officer
  • Carole Piwnica · Director
  • Fernando Reinach · Director
  • Geoff Duyk · Director
  • John Doerr · Director
  • Ralph Alexander · Director
  • Samir Kaul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tamara Tompkins, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Apr 2, 2010. Read the notice at the SEC.

equitySEC
Feb 2008$2 MNo. 1$2 to $10 million

Amyris Biotechnologies Inc.: Raise no. 1, Feb 2008

Investors in this round

3 investors had bought by the notice of Aug 24, 2009: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Jack Newman · Executive Officer
  • Jeff Lievense · Executive Officer
  • Jeryl Hilleman · Executive Officer
  • Joel Cherry · Executive Officer
  • John Melo · Executive Officer, Director
  • Kinkead Reiling · Executive Officer, Director
  • Neil Renninger · Executive Officer
  • Tamara Tompkins · Executive Officer
  • Fernando Reinach · Director
  • Geoff Duyk · Director
  • John Doerr · Director
  • Ralph Alexander · Director
  • Samir Kaul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tamara Tompkins, Secretary. Source: SEC Form D, newest notice filed Aug 24, 2009. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Amyris Biotechnologies Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2022).

    SEC Form D · Sep 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2022

That is all the official record says: Amyris Biotechnologies Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Amyris Biotechnologies Inc. are on record.

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in Amyris Biotechnologies Inc.
InvestorKindAmountRoundRoleSource
DSM International B.V.Othernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Khosla Ventures Associates III, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Khosla Ventures Associates II, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Khosla Ventures III, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Khosla Ventures II, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Kleiner Perkins Caufield & Byers XII, LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Koninklijke DSM N.V.Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
KPCB XII Associates, LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
KPCB XII Founders Fund, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Total Gas & Power USA, SasPersonnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2010)SEC Form 3
VK Services, LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 35 rounds above had up to 53 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Amyris Biotechnologies Inc.
NameRoleNamed in
Eduardo AlvarezChief Operating OfficerSep 2022
Hermanus KieftenbeldChief Financial OfficerSep 2022
John MeloPresident and Chief Executive OfficerSep 2022
Nicole KelseyChief Legal Officer & SecretarySep 2022
Han John KeiftenbeldChief Financial OfficerJun 2020
Jonathan Neil WolterInterim Chief Financial OfficerFeb 2020
Kathleen ValiasekChief Business OfficerFeb 2020
Joel CherryPresident of R&DMay 2019
Raffi AsadorianExecutive officerNov 2016
Nicholas KhadderExecutive officerMay 2016
Paulo DinizExecutive officerApr 2014
Susanna McfersonExecutive officerApr 2014
Gary LoebExecutive officerApr 2013
Steven R. MillsExecutive officerApr 2013
Peter BoyntonExecutive officerJan 2013
Mark R. PatelExecutive officerJun 2012
Jeryl HillemanExecutive officerMar 2012
Mario PortelaExecutive officerMar 2012
Neil RenningerExecutive officerMar 2012
Tamara TompkinsExecutive officerMar 2012
Jack NewmanExecutive officerOct 2010
Jeff LievenseExecutive officerOct 2010
Kinkead ReilingExecutive officerOct 2010
Ana John DutraDirectorSep 2022
Frank John KungDirectorSep 2022
Geoffrey John DuykDirectorSep 2022
James John MccannDirectorSep 2022
John MeloPresident and Chief Executive OfficerSep 2022
Julie John WashingtonDirectorSep 2022
L John DoerrDirectorSep 2022
Lisa John QiDirectorSep 2022
Philip John EykermanDirectorSep 2022
Ryan John PanchadsaramDirectorSep 2022
Steven John MillsDirectorSep 2022
Carole John PiwnicaDirectorJun 2020
Christoph John GoppelsroederDirectorJun 2020
Patrick John YangDirectorJun 2020
James Neil MccannDirectorFeb 2020
Lisa Neil QiDirectorFeb 2020
Patrick Neil YangDirectorFeb 2020

About

Sustainable synthetic ingredients for consumer products.